Clinical trials: Schizophrenia and Disorders With Psychotic Features
- Condition Schizophrenia and Disorders With Psychotic Features
- Funder type Industry (pharma, biotech, devices)
Schizophrenia
Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
To assess the effectiveness of aripiprazole once-monthly in the maintenance treatment of patients with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text…
- Trial name
- NCT01795547
- Testing
- Aripiprazole and aripiprazole once-monthly, Paliperidone and paliperidone palmitate
- Where
- 2 sites in United States
- Volunteers
- 295 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Antipsychotics
MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics
Interventional, multicenter, open-label, 20 weeks study To identify efficacy and safety in switching from oral aripiprazole to Abilify Maintena.
- Conditions
- Schizophrenia, Antipsychotics, Long-Acting Injection, LAI
- Trial name
- MAESTRO (NCT03376763)
- Testing
- Abilify maintena
- Where
- 27 sites in South Korea
- Volunteers
- 201 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.
- Trial name
- 02VNS2009 (NCT01176721)
- Testing
- t-VNS verum
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- cerbomed GmbH
Schizophrenia
A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
Confirm the tolerability and safety of long-term administration of the brexpiprazole QW formulation in patients with schizophrenia
- Trial name
- NCT05326347
- Testing
- OPC-34712FUM/ Brexpiprazole fumarate
- Where
- Japan
- Volunteers
- 247 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Neuromodulation for Schizophrenia
Our proposed study employs a novel approach to determine the clinical and functional imaging effects of brainstem neuromodulation, with an investigational study device, on illness awareness in schizophrenia - a significant…
- Trial name
- NCT05580211
- Testing
- Non-invasive brainstem modulation device (stimulation Randomized), Non-invasive brainstem modulation device (stimulation-Open Label)
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- Scion NeuroStim
Schizophrenia
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
To compare inpatient psychiatric hospitalization rates while participants are on oral standard-of-care antipsychotic treatment and later switched to Abilify MyCite®.
- Trial name
- NCT03892889
- Testing
- Abilify MyCite®
- Where
- 68 sites in United States
- Volunteers
- 277 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Efficacy of Lu 31-130 in Patients With Schizophrenia
The main purpose with the study is to evaluate the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to placebo.
- Trial name
- NCT00768326
- Testing
- Zicronapine
- Where
- Germany
- Volunteers
- 280 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020
A Six-Week, Randomized, Double-Blind, Parallel Group Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 Compared To Risperidone, In Schizophrenic Patients Previously…
- Trial name
- NCT00722176
- Testing
- BL-1020, BL-1020 10-30 mg, risperidone
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- BioLineRx, Ltd.
Cognitive Dysfunction, Schizophrenia
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years
This first-in-human clinical trial with a randomized, double-blind, placebo-controlled, dose-escalation study design is regarded as standard to test the safety, tolerability, and pharmacokinetics of KYN-5356.
- Trial name
- NCT06225115
- Testing
- KYN-5356
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Kynexis B.V.
Schizophrenia
Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia
This is a 12-week study for the treatment of chronic persistent symptoms in participants with schizophrenia. Participants on a stable, optimal dose of up to two atypical antipsychotics who fulfill the screening criteria will be…
- Trial name
- NCT00086593
- Testing
- lamotrigine
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 209 people
- Sponsor
- GlaxoSmithKline
Schizophrenia
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
The purpose of this study is to evaluate the feasibility of conducting a study of oral risperidone followed by paliperidone palmitate for once monthly (PP1M) and paliperidone palmitate for every 3 months (PP3M) in rwandan…
- Trial name
- NCT03713658
- Testing
- Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., Paliperidone Palmitate 75 mg eq.
- Where
- 3 sites in Rwanda
- Volunteers
- 34 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
Efficacy Study on Cognitive Functions in Schizophrenic Patients
Primary objectives To compare neurocognitive effects of amisulpride with those of risperidone in patients with chronic schizophrenia, as assessed by the general cognitive index, a measure of overall cognitive functioning in…
- Trial name
- AMIMIND (NCT00761670)
- Testing
- amisulpride and risperidone
- Where
- Hungary
- Volunteers
- 37 people
- Sponsor
- Sanofi
Schizophrenia
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in…
- Trial name
- NCT05227703
- Testing
- Emraclidine 15 mg, Emraclidine 30 mg
- Where
- 26 sites in United States, Bulgaria and 1 more
- Volunteers
- 391 people
- Sponsor
- AbbVie
Schizophrenia
Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials
The purpose of this study is to provide aripiprazole to schizophrenic outpatients and Community Treated Patients who are currently receiving aripiprazole therapy on another BMS sponsored clinical trial.
- Trial name
- NCT00239356
- Testing
- Aripiprazole
- Where
- 20 sites in Canada, Croatia and 9 more
- Volunteers
- 119 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia and Disorders With Psychotic Features
One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist…
- Trial name
- NCT00748566
- Testing
- Ziprasidone HCL (oral)
- Where
- 32 sites in Canada
- Volunteers
- 172 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
The primary purpose of this study is to determine whether a combination of ACP-103 (the study medication) with either haloperidol or risperidone will show antipsychotic efficacy and that it is safe and well tolerated.
- Trial name
- NCT00361166
- Testing
- ACP-103
- Where
- 17 sites in United States, Brazil
- Volunteers
- 400 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia, Schizoaffective Disorder
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
The study will determine the safety, tolerability, and pharmacokinetics of aripiprazole lauroxil in adults with schizophrenia or schizoaffective disorder.
- Trial name
- NCT02636842
- Testing
- Aripiprazole Lauroxil
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alkermes, Inc.
Psychotic Disorders
Improving Cognitive Function of Aripiprazole in Treating Adolescents and Young Adults With Psychotic Disorder
This is a 24-week, observational, prospective study to evaluate the effectiveness of improving cognitive function of aripiprazole in treating adolescents and young adults with psychotic disorder in Taiwan.
- Trial name
- NCT00541502
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Schizophrenia
An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia
The purpose of this study is to evaluate the tolerability, safety and treatment response of flexible doses of paliperidone extended-release (ER; designed to slowly release a drug in the body over an extended period of time)…
- Trial name
- PERTAIN (NCT00566631)
- Testing
- Paliperidone
- Where
- 30 sites in Croatia, France and 5 more
- Volunteers
- 294 people
- Sponsor
- Janssen-Cilag International NV
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.